Dr. Eric Joel Meinhardt, MD

Dr. Meinhardt practices at Barrington Surgery Center, LLC in Los Angeles, California.

Dr. Meinhardt's NPI, 1033436654, was assigned on April 21, 2010. Dr. Meinhardt graduated from UCSF School of Medicine in 2009. Dr. Meinhardt holds California license A113988.

Dr. Meinhardt's primary practice is Barrington Surgery Center, LLC, at 11645 W Wilshire Blvd, Los Angeles, CA 90025 in Los Angeles County. The practice phone is (310) 289-8600.

Dr. Meinhardt's primary practice is Barrington Surgery Center, LLC in Los Angeles, California. The medical group on file is California Dermatology Specialists. Dmand AI also links Dr. Meinhardt to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meinhardt practices. Vendor and product names are available with a free account.

Dermatology is Dr. Meinhardt's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Meinhardt is board certified in dermatology by the American Board of Dermatology. Dr. Meinhardt is licensed in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, itchy rashes, joint cyst and minor head injury among the conditions Dr. Meinhardt treats.

CMS data shows 1,805 Medicare services from Dr. Meinhardt across 12 procedure codes in 2024, for 296 Medicare patients. Medicare paid $71,735 for them. Every service was in an office.

CMS counts 296 Medicare patients who saw Dr. Meinhardt in 2024. The largest group is 65 to 74, with 150 patients. 75% of them have high cholesterol, and 55% have high blood pressure. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Meinhardt's median patient age at 38, with 47% women.

In 2024, Dr. Meinhardt wrote 347 Medicare Part D claims for 114 patients. 93% of them were for generic drugs. CMS names the drug for 284 of them, across 11 drugs with 11 or more claims each, at $52,463 in total drug cost. In 2023, CMS named 219 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Meinhardt for performance year 2024, reported individually. Dr. Meinhardt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 480 procedures of removal of skin lesions by Dr. Meinhardt, more than 86% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Meinhardt in 2015. Dr. Meinhardt's most frequent co-authors are Kathryn Joyce Martires, MD and Kumar Sukhdeo, MD, PhD.

CMS Open Payments shows 400 general payments to Dr. Meinhardt from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $1,530.

Dr. Meinhardt graduated from UCSF School of Medicine in 2009.

Dr. Meinhardt is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.